KETO-TUMOR: a Study on Brain Tumors and Central Obesity
Recruiting
N/A
Interventional Study
Obese Patients
Hypothalamic Neoplasms
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 7 – 30
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Meyer Children's Hospital IRCCS · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hypothalamic-chiasmatic tumours account for 5-10% of CNS tumours in children and can compromise hypothalamic function, causing alterations in energy balance and weight gain. In inoperable cases, chemotherapy and radiotherapy are used; the latter, although the gold standard, is associated with significant neurocognitive and endocrine-metabolic side effects, proportional to the hypothalamic damage.
…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis of hypothalamic-chiasmatic tumour according to the WHO 2021 classification
2. Diagnosis of hypothalamic obesity: after 5 years of age, BMI \>97th percentile in the WHO 2007 curves
3. Males and females aged between 7 and 30 years
4. Performance status: Lansky score \…
Contacts